

**Anti-DLL4 Reference Antibody (navicixizumab)
Recombinant Antibody
Catalog # APR10040****Specification**

Anti-DLL4 Reference Antibody (navicixizumab) - Product Information

Application	FC, E, FTA
Primary Accession	O9NR61
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	146.17 KDa

Anti-DLL4 Reference Antibody (navicixizumab) - Additional Information**Target/Specificity**
DLL4**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-DLL4 Reference Antibody (navicixizumab) - Protein Information****Name** DLL4**Function**
Involved in the Notch signaling pathway as Notch ligand (PubMed:11134954). Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting (PubMed:20616313). Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types (By similarity). During spinal cord neurogenesis, inhibits V2a interneuron fate (PubMed:17728344).**Cellular Location**
Cell membrane; Single-pass type I membrane protein


Tissue Location

Expressed in vascular endothelium.


Anti-DLL4 Reference Antibody (navicixizumab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-DLL4 Reference Antibody (navicixizumab) - Images

Anti-DLL4 Reference Antibody (navicixizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-DLL4 Reference Antibody (navicixizumab) is more than 95%, determined by SEC-HPLC.



Immobilized human VEGF165 His at 2 µg/mL can bind Anti-DLL4 Reference Antibody (navicixizumab) \square EC₅₀=0.01191 µg/mL